Suggestions
Eugene Krentsel
Innovator. Connector. Builder.
Eugene Krentsel is an accomplished professional with expertise in leadership in technology commercialization, entrepreneurship, non-dilutive funding, SBIR/STTR, knowledge transfer, research management, proof-of-concept centers, innovation-based economic development, and technology assessment.
He pursued a PhD in Chemistry at the Institute of Chemical Physics, Russian Academy of Sciences, showcasing a strong academic background in the field.
Eugene Krentsel has held key positions in various organizations, including Chief Scientific Officer and Vice President for Strategic Partnerships and Alliances at XLerateHealth, Co-Founder and President at innoVEK, LLC, Senior Advisor at XLerateHealth, MPI at ExCITE Program @ UofL (an NIH REACH Hub), and Executive Committee Member at APLU's Commission on Innovation, Competitiveness, and Economic Prosperity (CICEP).
His extensive professional experience also includes serving as Associate Vice President, Research and Innovation at the University of Louisville, Advisory Committee Member at the National Science Foundation SBIR/STTR, Assistant Vice President for Entrepreneurship and Innovation Partnerships at Binghamton University, Assistant Vice President for Technology Transfer and Innovation Partnerships at Binghamton University, and Director of the International Technology Commercialization Institute at the University of Missouri.
Highlights
What you don’t know can hurt you!
Do you understand the differences between SBIR/STTR “omnibus” and targeted solicitations? Ever wondered which one is more advantageous for your company? Do you know what “omnibus” even means?
Join me as I host a unique webinar on Wednesday, September 11th, at 3 pm Eastern, with representatives of 4 top institutes at The National Institutes of Health - National Cancer Institute (NCI); National Heart, Lung, and Blood Institute; National Institute on Aging (NIA); and National Institute of Neurological Disorders and Stroke (NINDS) - to hear about the opportunities and differences between applying through investigator-initiated “omnibus” notices of funding opportunities (where an applicant proposes research topic of their own choosing, based on the general areas of interest states in the general solicitation from NIH) and special targeted SBIR/STTR offerings (where certain NIH institutes or centers seek innovative solutions to specific ailments or topics, e.g., Alzheimer’s).
You will also hear about valuable support programs for entrepreneurs and small businesses available through XLerateHealth and the NIH-sponsored XLerator Network.
Participation is free. Registration link is in the comments section below.
Congratulations to Dr. Brett Janis, CEO of DesiCorp Inc, who just received the 2024 Entrepreneur Award at the 9th National IDeA Symposium of Biomedical Research Excellence in Washington, DC! 🚀🚀🚀
#TheWinner Michael Menze Jonathan Kopechek XLerateHealth University of Louisville
